HomeComparePPTTF vs ABBV

PPTTF vs ABBV: Dividend Comparison 2026

PPTTF yields 6.80% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $83.8K in total portfolio value
10 years
PPTTF
PPTTF
● Live price
6.80%
Share price
$11.40
Annual div
$0.78
5Y div CAGR
-49.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.9K
Annual income
$0.73
Full PPTTF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — PPTTF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPPTTFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PPTTF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PPTTF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PPTTF
Annual income on $10K today (after 15% tax)
$578.25/yr
After 10yr DRIP, annual income (after tax)
$0.62/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,866.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PPTTF + ABBV for your $10,000?

PPTTF: 50%ABBV: 50%
100% ABBV50/50100% PPTTF
Portfolio after 10yr
$62.8K
Annual income
$12,863.23/yr
Blended yield
20.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PPTTF
No analyst data
Altman Z
1.7
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PPTTF buys
0
ABBV buys
0
No recent congressional trades found for PPTTF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPPTTFABBV
Forward yield6.80%3.12%
Annual dividend / share$0.78$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-49.8%40.6%
Portfolio after 10y$20.9K$104.7K
Annual income after 10y$0.73$25,725.73
Total dividends collected$700.00$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PPTTF vs ABBV ($10,000, DRIP)

YearPPTTF PortfolioPPTTF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,042$341.51$11,559$438.51$517.00ABBV
2$11,991$176.91$13,494$640.86$1.5KABBV
3$12,921$90.14$15,951$945.97$3.0KABBV
4$13,871$45.57$19,152$1,413.89$5.3KABBV
5$14,865$22.95$23,443$2,146.38$8.6KABBV
6$15,917$11.54$29,391$3,321.96$13.5KABBV
7$17,037$5.80$37,948$5,265.87$20.9KABBV
8$18,232$2.91$50,795$8,596.74$32.6KABBV
9$19,510$1.46$71,034$14,549.41$51.5KABBV
10$20,877$0.73$104,715$25,725.73$83.8KABBV

PPTTF vs ABBV: Complete Analysis 2026

PPTTFStock

Perpetual Limited is a publicly owned investment manager. The firm offers a range of financial products and services in Australia. The company provides funds management, portfolio management, financial planning, trustee, responsible entity and compliance services, executor services, investment administration and custody services, and mortgage processing services. It offers investment capabilities across a range of asset classes, including Australian and global equities, mortgages, cash and fixed interest, and Australian listed property. The company also provides specialist direct-to-client financial services for high net worth individuals that include fiduciary services, such as trust advice and services, custodial solutions, estate planning, estate administration, and executorial services; independent financial advice services with specialist and 'do-it-yourself' superannuation offerings; and philanthropic services. In addition, it offers corporate trustee and transaction support services, including trustee services for mortgage backed and other securitization programs for major banks and non-bank financial institutions; mortgage services, including mortgage preparations, variations and discharges; post settlement servicing; regulatory compliance services for fund managers; custody, unit registry, and accounting services for property and mortgage funds; and trusteeships for corporate debt issues and infrastructure projects. The company was founded in 1886 and is based in Sydney, Australia with additional offices in Adelaide, Brisbane, Canberra, Melbourne and Perth.

Full PPTTF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PPTTF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PPTTF vs SCHDPPTTF vs JEPIPPTTF vs OPPTTF vs KOPPTTF vs MAINPPTTF vs JNJPPTTF vs MRKPPTTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.